DURECT, Zogenix, Terminate Development and License Deal

Published: Aug 03, 2017

As of August 1, 2017, DURECT and Zogenix, Inc. have terminated their Development and License Agreement (dated July 11, 2011, as amended) whereby Zogenix had the worldwide development and commercialization rights to Relday®.Relday is an investigational long-acting formulation of risperidone, an atypical anti-psychotic agent.Under the mutual termination agreement, Zogenix’s development and commercialization rights are returned to DURECT, and Zogenix will transfer to DURECT all regulatory filings and development information related to Relday.

Back to news